The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 02, 2019
Filed:
Sep. 13, 2018
Applicant:
Glaxosmithkline Intellectual Property Development Limited, Brentford, Middlesex, GB;
Inventors:
Weichun Chen, Shanghai, CN;
Ebere F Igboko, Collegeville, PA (US);
Xichen Lin, Shanghai, CN;
Hongfu Lu, Shanghai, CN;
Feng Ren, Shanghai, CN;
Paul Bryan Wren, Uxbridge Middlesex, GB;
Zhongmiao Xu, Shanghai, CN;
Ting Yang, Shanghai, CN;
Lindong Zhu, Shanghai, CN;
Assignee:
GlaxoSmithKline Intellectual Property Development Limited, Brentford, Middlesex, GB;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 307/18 (2006.01); C07D 241/04 (2006.01); C07D 309/08 (2006.01); C07C 317/50 (2006.01); C07C 317/42 (2006.01); C07C 311/47 (2006.01); C07D 305/06 (2006.01); C07D 213/34 (2006.01); C07D 295/135 (2006.01); C07D 211/54 (2006.01); C07D 207/10 (2006.01); C07D 487/04 (2006.01); C07D 471/04 (2006.01); C07D 239/26 (2006.01); C07D 233/64 (2006.01);
U.S. Cl.
CPC ...
C07D 307/18 (2013.01); C07C 311/47 (2013.01); C07C 317/42 (2013.01); C07C 317/50 (2013.01); C07D 207/10 (2013.01); C07D 211/54 (2013.01); C07D 213/34 (2013.01); C07D 233/64 (2013.01); C07D 239/26 (2013.01); C07D 241/04 (2013.01); C07D 295/135 (2013.01); C07D 305/06 (2013.01); C07D 309/08 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/10 (2017.05); C07C 2601/14 (2017.05);
Abstract
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.